Bxq-350- A Phase 1, Dose-Escalation, Open-Label, Safety And Pharmacokinetic, First In Human Study Of Bxq-350 Administered As A Single Agent By Intravenous Infusion In Adult Patients With Advanced Solid Tumors And Recurrent High-Grade Gliomas
Posted Date: Jul 26, 2017
- Investigator: John Morris
- Specialties: Hematology/Oncology, Oncology, Cancer
- Type of Study: Drug
The purpose of this study is to test the safety of BXQ-350, an investigational drug, at different doses to find out what effects, if any, it has on people with cancer. An investigational drug means the drug is being tested and is not approved for sale by the regulatory authorities (such as Food and Drug Administration (FDA). This drug has been tested in animals but not yet in people. A second purpose of this study is to see if the dose determined to be safer is also effective at slowing or stopping the growth of cancer.
To Be Eligible To Participate In This Study, Participants Must Have Advanced Solid Tumor Cancer Or A Specific Type Of Brain Cancer, Have Already Been Treated With Surgery, Radiation, And/Or Chemotherapy And The Cancer Is Now Growing.
Solid Tumors, Brain, Bxq-350, Cancer, Phase I
For More Information:
Uc Cancer Institute